Vertebroplasty for osteoporotic fracture? Think twice by Kinkade, Scott et al.
654 THE JOURNAL OF FAMILY PRACTICE  |   DECEMBER 2009  |   VOL 58, NO 12
Priority Updates from the Research Literature 
from the Family Physicians Inquiries Network
and therapy for osteoporosis. Since the late 
1990s, however, vertebroplasty (VP)—the per-
cutaneous injection of acrylic bone cement 
(polymethylmethacrylate, or PMMA) into the 
aff ected vertebra under radiologic guidance—
has become the preferred treatment, particu-
larly for painful vertebral fractures that do not 
respond to conservative treatment. 
Widely used, but not much evidence 
Despite a lack of rigorous scientifi c evidence 
of VP’s effi  cacy, the number of procedures 
nearly doubled from 2001 to 2005 among 
Medicare enrollees—from 45 per 100,000 to 
87 per 100,000.4 A meta-analysis of 74 (mostly 
observational) studies of VP for osteoporotic 
compression fractures found good evidence 
for improved pain control in the fi rst 2 weeks. 
At 3 months, the analysis found only fair evi-
dence of benefi t, and at 2 years, there was no 
apparent benefi t.5
Complications are primarily related to 
cement extravasation, but are usually not 
symptomatic. Th e overall symptomatic com-
plication rate is less than 4%.6 Th ere is confl ict-
ing evidence regarding whether VP increases 
the risk of fracture in other vertebrae.7 
Prior to the 2 studies reviewed in this 
PURL, there were only 2 RCTs comparing ver-
tebroplasty with conservative medical man-
agement. Th e VERTOS trial8 randomized 34 
people with osteoporotic vertebral compres-
sion fractures (of 6 weeks’ to 6 months’ du-
ration and refractory to medical therapy) to 
either VP or conservative treatment. Th e VP 
patients had improved pain scores and de-
Vertebroplasty for osteoporotic 
fracture? Th ink twice 
Two new studies suggest that this widely used procedure 
should be used less often—and more cautiously. 
PRACTICE CHANGER
Th ink twice before recommending vertebroplasty 
(VP) for symptomatic osteoporotic compression 
fractures. New studies suggest that it has little 
benefi t; thus, VP should be considered only af-
ter other, more conservative options fail.1,2 
STRENGTH OF RECOMMENDATION
A: Consistent, high-quality randomized con-
trolled trials (RCTs) 
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ILLUSTRATIVE CASE
A 72-year-old woman with a history of osteo-
porosis is being treated with a bisphospho-
nate, calcium, and vitamin D. She’s in your 
ofﬁ ce today because of the sudden onset of 
midline lower back pain after minor trauma. 
X-ray reveals an uncomplicated osteoporotic
fracture of L2, with 50% loss of vertebral 
height. When she returns in a few weeks, the 
patient still has signiﬁ cant pain (7 on a scale 
of 0-10) that is not well controlled with hydro-
codone and acetaminophen. Should you refer 
her for vertebroplasty?
 
Each year in the United States, approxi-mately 750,000 vertebral fractures oc-cur.3 Th e traditional treatments for 
osteoporotic vertebral compression fractures 
include bed rest, pain medication, braces, 
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teum of the vertebra. Th e PMMA 
was opened and mixed in the 
room to allow its distinctive smell 
to permeate. Patients also re-
ceived verbal and physical cues 
that simulated the procedure, 
and spinal images were obtained. 
❚ INVEST used pain and disability at 
1 month as the primary end points. Th ere was 
minimal diff erence in pain intensity (3.9 on 
VAS for the VP group, vs 4.6 for the controls). 
Th ere was also little diff erence in back pain-
related disability at 1 month, with scores on 
the Roland Morris Disability scale decreasing 
(from a baseline of 16.6 for the VP group and 
17.5 for the control group) to 12 and 13, respec-
tively (P=.49). Nor were there any statistically 
signifi cant diff erences in pain or disability at 
earlier intervals (the researchers compared 
the scores of the VP and control groups at 
3 days and 14 days.) Th e authors also looked 
at 7 other measures of pain and functioning 
and found no signifi cant diff erences in any of 
them at the end of 1 month. 
To encourage enrollment, patients in the 
INVEST trial were allowed to cross over after 
1 month. At that time, 12% of those in the VP 
group and 43% of those in the control group 
took advantage of this provision and had the al-
ternate “procedure.” Both groups of cross-over 
patients had more pain than those who did 
not make the switch. Although both of these 
groups showed improvement at the 3-month 
mark, they still had higher pain levels than 
their counterparts who did not cross over. 
❚ The Buchbinder study used overall 
pain on a 10-point VAS at 3 months as its 
primary end point. Th e researchers also re-
corded 7 other measurements and assessed 
participants at 1 week, 1 month, 3 months, 
and 6 months. At 3 months, there was no 
signifi cant diff erence in the change in pain 
scores between the treatment and placebo 
groups: Mean pain scores for those who un-
derwent VP decreased from 7.4 to 5.1, while 
the placebo group’s average pain scores went 
from 7.1 to 5.4. Similarly, there was no dif-
ference between the treatment and placebo 
groups in the change in pain scores at 1 week 
or 6 months—and no diff erence between the 
groups at any time for the other 7 measures of 
pain and function. 
creased use of analgesic agents at 
24 hours, compared with the con-
servative treatment group. But at 
the end of the 2-week trial, there 
was no diff erence in pain scores 
between the 2 groups. 
Th e other RCT of VP vs conservative ther-
apy randomized 50 patients with acute or sub-
acute osteoporotic fractures (the average age 
of fracture was 6-8 days) to VP or conservative 
care.9 Th ere was signifi cant pain improvement 
in VP patients at 24 hours, but no signifi cant dif-
ference in pain scores between the 2 groups at 
3 months. Th is study was signifi cantly fl awed, 
however, because the researchers failed to col-
lect pain measurements at study entry for a 
substantial number of patients. 
STUDY SUMMARIES 
Vertebroplasty lacks beneﬁ ts
Both INVEST (the Kallmes study)1 and the 
 Buchbinder study2 were blinded, random-
ized, placebo-controlled trials of VP. INVEST, 
performed at 11 sites in the United States, 
United Kingdom, and Australia, enrolled 131 
patients. Th e Buchbinder study enrolled 78 
patients at 4 sites in Australia. Both enrolled 
patients with painful osteoporotic fractures 
of less than 1 year’s duration. Exclusions for 
both trials included a suspicion of neoplasm 
in the vertebral body, substantial retropulsion 
of bony fragments, medical conditions that 
would preclude surgery, and an inability to 
obtain consent or conduct follow-up. 
Participants in both trials had similar 
baseline characteristics: Th ey were primarily 
Caucasian and female, with an average age 
in the mid-70s. Th e average pain intensity at 
enrollment was about 7 on a 0- to 10-point 
visual analog scale (VAS). Th e average time 
since the fracture causing the pain was 4 to 5 
months in INVEST and about 2 months in the 
Buchbinder study. Both trials used appropri-
ate randomization, blinding, and intention-
to-treat analysis. 
❚ Blinding featured sham procedures.
In both studies, the researchers used elabo-
rate measures to ensure blinding: Th e con-
trol patients were prepped in the fl uoroscopy 
suite as if they were about to undergo VP. Th ey 
received local anesthesia down to the perios-
INSTANT 
POLL 
QUESTION
Under what 
circumstances do 
you recommend 
vertebroplasty 
for a patient with 
an osteoporotic 
compression 
fracture? 
(Check all that apply) 
•  Shortly after the 
fracture is diagnosed.
•  Only after conservative 
treatment has failed 
to bring pain relief. 
•  On a case-by-case 
basis, depending 
on factors such as 
compression severity, 
duration of fracture, 
level of pain, and 
comorbidities. 
•  None; I do not 
recommend VP 
for osteoporotic 
compression fracture.
•  Other ______________
Go to jfponline.com
and take our instant poll 
CONTINUED
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WHAT’S NEW
Trials cast doubt on established 
procedure
VP has essentially become the standard of 
care for painful osteoporotic vertebral frac-
tures, bolstered by a long list of methodologi-
cally inferior studies that have lent support to 
the procedure’s effi  cacy. Th ese 2 studies are 
the fi rst to incorporate a sham procedure that 
supports true placebo control. Th e complete 
lack of benefi t for VP compared with con-
servative management in these well-done 
trials calls into question the results of prior 
reports. 
CAVEATS
Sample size, study design
Researchers in both studies had consider-
able diffi  culty enrolling patients. Both were 
multi center trials and enrolled patients over a 
4-year period; nonetheless, taken together, 
only about 200 patients consented. Th e re-
searchers faced opposition from referring 
doctors and patients alike, who believed that 
the possibility of receiving a placebo treat-
ment rather than VP constituted inferior care. 
In addition to their relatively small size, 
these studies enrolled patients with fairly 
chronic fractures. It has been postulated that 
VP has a higher likelihood of success with 
acute fractures, but that was not the focus of 
these trials. Th e majority of the fractures in 
trial participants were not acute (<4 weeks). 
Neither trial was designed for analysis based 
on the chronicity of the fracture, and neither 
found a diff erence in outcome based on frac-
ture duration. 
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Because these trials were not designed, 
or robust enough, for subgroup analysis, 
we don’t know if there is a population that 
might benefi t (ie, severity of the compres-
sion, acuteness of the fracture, or premorbid 
health, etc). In addition, these results do not 
apply to the use of VP for other reasons—ma-
lignant spinal neoplasms or vertebral hem-
angiomas, for example. 
Finally, it is important to remember that 
these trials did not strictly compare VP with con-
servative treatment. Th e sham treatment may 
have had signifi cant placebo power that is great-
er than that of typical conservative treatment. 
CHALLENGES TO IMPLEMENTATION
Support for VP is well established
Anecdotal results, established treatment pat-
terns, and numerous low-quality studies sup-
port the use of VP for vertebral compression 
fracture. Medicare and other insurers had 
reviewed the evidence prior to these 2 trials 
and agreed to reimburse for the procedure. It 
remains to be seen whether these 2 trials will 
be suffi  cient to overcome these barriers and 
change practice patterns. 
At a minimum, however, it is prudent to 
reserve VP for patients who have intractable 
symptoms until further trials are undertaken to 
determine whether VP really works, and if so, 
for which patients.               
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In 2005, 
the rate of 
vertebroplasty 
among Medicare 
beneﬁ ciaries 
was 87 per 
100,000—nearly 
double the 
2001 rate.
656_JFP1209   656 11/17/09   12:08:52 PM
